The healthcare sector is easily the worst performing group in 2019 as political rhetoric continues to drive the negative sentiment.Given that the sector has trailed the S&P 500 by 12% in 2019, is the group becoming a buy low opportunity? I think so.Most of the concern surrounding the group is politically motivated. There are renewed threats to gut Obamacare and conversations continue around trying to lower drug prices. The introduction of a "Medicare For All" plan also hangs over the group despite the fact that is seems like a long shot to ever be put in place. All of these raise uncertainty about the ability of healthcare companies to drive continued revenue and earnings growth.But are we likely to see any of these implemented in the near future? A split Congress will make it difficult for any meaningful reform to pass before the 2020 election and probably even longer given that a post-election split Congress still seems likely.On the fundamental side, balance sheets are still strong with healthy levels of cash on hand and with a forward P/E ratio of under 16 the sector is quite reasonably valued. If you're interested in taking at swing at healthcare stocks at these levels, here are three ETFs to consider.Healthcare Select Sector SPDR ETF (XLV)If you want broad exposure to the sector, this is your best bet. It's got about one-third of the portfolio in pharma with 24% in healthcare equipment, 19% in healthcare providers and 16% in biotech. The allocation to healthcare providers has been a drag on the portfolio in 2019, but the remainder of the fund has actually performed relatively well.iShares U.S. Medical Devices ETF (IHI)The medical device group has been one of healthcare's best-performing subsectors as the industry experiences a renaissance in robotics and technology. The good news is that this group has been a strong performer for about two straight years. The bad news is that the group is pretty expensive.SPDR S&P Pharmaceuticals ETF (XPH)Yes, the pharmaceuticals group is likely going to be a target of Washington through the 2020 election cycle but again I don't see there being significant change to the way drugs are priced any time soon. The somewhat irrational fear that pharma companies will be under pressure in the near-term seems unlikely.What do you think? Are you adding healthcare stocks to your portfolio? Comment down below!